Agoracom Blog

FEATURE: GrowPros (GCI:CSE) Natural Pharmaceuticals From Cannabis and Other Medicinal Plants $GCI.ca

Posted by AGORACOM-JC at 3:52 PM on Wednesday, August 10th, 2016

Growpros_hub_large

Natural Pharmaceuticals Derived From Cannabis and Other Medicinal Plants

Comprised Of Two Divisions

Pharmaceutical Division – PhytoPain Pharma

  • A new subsidiary created June 2, 2016. 80% Ownership
  • Mission is the development and commercialization of botanical based pharmaceuticals
  • A clinical stage drug development company engaged in the development of medication to alleviate symptoms related to: Pain,
    Insomni, anxiety disorder, in patients suffering from Cancer and othe, chronic and terminal diseases

Dr Guy Chamberland, Chief Scientific Officer and Regulatory Affairs

  • Professor of herbal medicine and clinical research at the École d’Enseignement Supérieur de Naturopathie du Québec.
  • 22 years’ experience in the pharmaceutical and natural product industries includes successful development of intellectual property for several botanical drug products

WHY DOCTORS NEED PHARMA MARIJUANA SOLUTIONS

  • A Physician’s decision to prescribe a new drug or even a natural health product has to be based on Evidence-Based Medicine > A legal, ethical requirement
  • Currently, no body of evidence exists to not support the prescription or recommendation of medical marijuana in any medical condition, including terminal cancer
  • The GrowPros pharmaceutical product development plan would provide the data necessary for physicians to prescribe or recommend our products

PRODUCT PIPELINE

Insomnia Management For Patients With Chronic Pain

  • Licensed a hypnotic drug from Mondias Naturals Inc
  • Management of Insomnia in patients with chronic pain
  • Currently in late stage Phase III clinical testing

PhytoPain To Produce A Combination Product

  • Proprietary combination expected to reach Phase I clinical testing in 2017
  • Will be ready for market in 2017 due to combination with Mondias Naturals product

Pain Management – Inhalation Cannabis Drug Product

  • A prescription drug for management of uncontrolled pain in cancer patients
  • Health Canada will provide guidance during Phase I clinical trial
  • Commencing December 2016. Anticipating 3-5 year product development

A recent discussion with the Quebec College of Physicians confirms that pharmaceutical development of a medical marijuana for inhalation would be well received by the medical community.

OPERATIONS OVERVIEW – MMPR

MMPR Division – Collaboration Agreement

  • March 18, 2016 – Signed agreement with Delta 9 Bio-Tech, a “Licensed Producer”
  • Delta 9 will submit to Health Canada an Amendment to collaborate on GrowPros previous application for facility in Southern Quebec; Amendment submission anticipated by June 30, 2106, Health Canada response anticipated August 30, 2016
  • Key Benefits of Delta 9 Collaboration: Significant process clarity, High probability of success eliminates spec construction risk, Single customer through option to acquire all dried marijuana product for 2 years
  • Key strategic benefit to GrowPros; Controlled production, quality and supply for Pharma Division, Value of license, Wholesale seller vs. retail seller

12 Month Stock Chart

Tags: , , ,

Comments are closed.